Confidential Project

BioFutureRx · BFRx3711

A novel long-acting GLP-1 analog engineered for potential once-monthly subcutaneous administration in obesity and type 2 diabetes, with preclinical efficacy benchmarked against semaglutide.

Download BioFutureRx · BFRx3711 ↓ Visit BioFutureRx ↗

Indication

Obesity / T2D

Projected Half-Life

~420–450 hr

Weight Reduction

19% (DIO mice)

Initial Ask

$10M

BioFutureRx · BFRx3711 — Investment Teaser Open in New Tab ↗ Download ↓

Loading the teaser… if it does not appear, use “Open in New Tab” or “Download” above.

Strictly confidential · Prepared by Intelligentzia Capital Management · Scroll within the frame to navigate pages

Discuss This Project

Explore BioFutureRx · BFRx3711